Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Retained Earnings (2021 - 2025)

Historic Retained Earnings for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$316.8 million.

  • Verrica Pharmaceuticals' Retained Earnings fell 894.49% to -$316.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$316.8 million, marking a year-over-year decrease of 894.49%. This contributed to the annual value of -$307.0 million for FY2024, which is 3323.05% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Retained Earnings stood at -$316.8 million for Q3 2025, which was down 894.49% from -$316.6 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Retained Earnings registered a high of -$104.8 million during Q1 2021, and its lowest value of -$316.8 million during Q3 2025.
  • For the 5-year period, Verrica Pharmaceuticals' Retained Earnings averaged around -$209.0 million, with its median value being -$181.0 million (2023).
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 4804.01% in 2024, then tumbled by 894.49% in 2025.
  • Verrica Pharmaceuticals' Retained Earnings (Quarter) stood at -$139.0 million in 2021, then dropped by 17.62% to -$163.5 million in 2022, then crashed by 40.99% to -$230.4 million in 2023, then tumbled by 33.23% to -$307.0 million in 2024, then fell by 3.2% to -$316.8 million in 2025.
  • Its last three reported values are -$316.8 million in Q3 2025, -$316.6 million for Q2 2025, and -$316.8 million during Q1 2025.